Randomized Multi-center Clinical Trial to Assess Effectiveness and Safety of Tirofiban Versus Intravenous Aspirin in Patients With Acute Ischemic Stroke Secondary to Tandem Injury, Subject to Recanalization Therapy Through Endovascular Treatment

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508454-26-00

Acronym

ATILA-ictus-2021

Enrollment

240

Registered

2024-04-30

Start date

2022-05-01

Completion date

Unknown

Last updated

2024-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Brief summary

Carotid Reocclusion, Platelet aggregation phenomena, Symptomatic intracranial hemorrhage (sICH)

Detailed description

Good functional prognosis, Defined as a score on the modified rankin scale (mRS) between 0-2 at 90 days.

Interventions

DRUGClopidogrel TecniGen 75 mg comprimidos recubiertos con película EFG

DRUGA.A.S. 100 mg comprimidos.

DRUGInyesprin

DRUGAGRASTAT 50 microgrammes/ml

DRUGsolution pour perfusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Carotid Reocclusion, Platelet aggregation phenomena, Symptomatic intracranial hemorrhage (sICH)	—

Secondary

Measure	Time frame
Good functional prognosis, Defined as a score on the modified rankin scale (mRS) between 0-2 at 90 days.	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026